MedTrace Logo

First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies

NCT04763083 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2023-07-07

No results posted yet for this study

Summary

NVG-111 is a bispecific antibody drug, having two "arms", one arm attaches to a substance on cancer cells called ROR1, the other arm attaches to the body's immune cells directing them to kill the cancer cells. This is the first clinical trial of the drug NVG-111, and will include patients with certain types of cancer including chronic lymphocytic leukaemia (CLL), small lymphocytic lymphoma (SLL) mantle cell lymphoma (MCL), follicular lymphoma (FL) and diffuse large B cell lymphoma (DLBCL) in Group A. Subjects with solid tumours, focusing initially on stage IV non-small cell lung cancer (NSCLC) or malignant melanoma.

Conditions

Interventions

DRUG

NVG-111

Open label, continuous iv infusion, escalating doses of NVG-111 for minimum 3 cycles

Sponsors & Collaborators

  • NovalGen Ltd.

    lead INDUSTRY

Principal Investigators

  • Parag Jasani, MBBS, FRCP, FRCPath · Royal Free London NHS Foundation Trust and University College London Hospitals

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-14
Primary Completion
2023-12-31
Completion
2025-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04763083 on ClinicalTrials.gov